The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, ...

WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...

We came across a bullish thesis on Nurix Therapeutics, Inc. on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NRIX. Nurix Therapeutics, Inc.’s share was trading ...

-- Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene -- IFLI contributed up to $9 million to Enterome's private funding round in 2025 -- Enterome has announced a ...

Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Background Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive biliary tract cancer with a poor prognosis and a complex tumour microenvironment (TME) that remains poorly understood.

B cell development in early life sets the stage for how the adaptive immune system will function. Although little is known about B cell biology in children, especially from tissue-residing B cells, it ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

B lymphocytes (B-cells) are a type of white blood cell important for immune function. They develop from stem cells through several stages. Malignancies in this lymphoid lineage can lead to acute ...